Ilaria Sammarra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ilaria Sammarra has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Gambardella
University “Magna Græcia” of Catanzaro
17 shared publications - Francesco Fortunato
Institute of Neurology, Department of Medical and Surgical Sciences Magna Graecia University of Catanzaro Catanzaro Italy
12 shared publications - Monica Gagliardi
Neuroscience Research Center, Magna Graecia University, 88100 Catanzaro, Italy
5 shared publications - Alessia Giugno
Institute of Neurology, Department of Medical and Surgical Sciences Magna Græcia University Catanzaro Italy
4 shared publications - Francesca Felicia Operto
Department of Health Sciences, Magna Graecia University of Catanzaro
4 shared publications - Mariagrazia Talarico
Research Center for Biochemistry and Applied Molecular Biology, Department of Experimental and Clinical Medicine Magna Græcia University Catanzaro Italy
4 shared publications
Latest Publications
Absence of familial adult myoclonic epilepsy‐associated intronic repeat expansions in SAMD12 , STARD7 , and MARCHF6 genes in juvenile myoclonic epilepsy with tremor
We investigated whether intronic repeat expansions in the SAMD12 , STARD7 , and MARCHF6 genes are present in individuals with juvenile myoclonic epilepsy (JME) and tremor. Given that tremor is a shared feature with familial adult myoclonic epilepsy (FAME), we hypothesized that this phenotype may reflect a common genetic basis involving FAME‐associated pentanucleotide repeat expansions. The study included 31 individuals with JME and tremor (17/31 [54.8%] females, mean age at genetic testing = 34.4 ± 13.8 years) and 100 age‐ and sex‐matched healthy controls. Genomic DNA was analyzed using repeat‐primed polymerase chain reaction and fragment analysis to detect intronic TTTCA repeat expansions in the three established FAME‐associated genes. No pathogenic repeat expansions were identified in SAMD12 , STARD7 , or MARCHF6 among individuals with JME and tremor. The frequency of intronic pentanucleotide repeat expansions did not differ between cases and controls. This is a comprehensive analysis assessing three FAME‐associated repeat‐expansion loci in a clinically well‐characterized cohort of individuals with JME and tremor. Our findings do not support a major contribution of these FAME‐associated loci to tremor in this cohort, suggesting that those intronic repeats did not contribute to genetic susceptibility to the tremor in JME. Further studies are required to identify the factors associated with this phenotype.
Absence of familial adult myoclonic epilepsy‐associated intronic repeat expansions in SAMD12 , STARD7 , and MARCHF6 genes in juvenile myoclonic epilepsy with tremor
We investigated whether intronic repeat expansions in the SAMD12 , STARD7 , and MARCHF6 genes are present in individuals with juvenile myoclonic epilepsy (JME) and tremor. Given that tremor is a shared feature with familial adult myoclonic epilepsy (FAME), we hypothesized that this phenotype may reflect a common genetic basis involving FAME‐associated pentanucleotide repeat expansions. The study included 31 individuals with JME and tremor (17/31 [54.8%] females, mean age at genetic testing = 34.4 ± 13.8 years) and 100 age‐ and sex‐matched healthy controls. Genomic DNA was analyzed using repeat‐primed polymerase chain reaction and fragment analysis to detect intronic TTTCA repeat expansions in the three established FAME‐associated genes. No pathogenic repeat expansions were identified in SAMD12 , STARD7 , or MARCHF6 among individuals with JME and tremor. The frequency of intronic pentanucleotide repeat expansions did not differ between cases and controls. This is a comprehensive analysis assessing three FAME‐associated repeat‐expansion loci in a clinically well‐characterized cohort of individuals with JME and tremor. Our findings do not support a major contribution of these FAME‐associated loci to tremor in this cohort, suggesting that those intronic repeats did not contribute to genetic susceptibility to the tremor in JME. Further studies are required to identify the factors associated with this phenotype.
- Open Access
- 8 September 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (6) , 3161-3178
Cenobamate Improves Emotional Dysregulation, Impulsivity, and Apathy in Drug-Resistant Focal Epilepsy: A Longitudinal Neuropsychological Study
- 8 September 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (6) , 3161-3178
Open AccessCenobamate Improves Emotional Dysregulation, Impulsivity, and Apathy in Drug-Resistant Focal Epilepsy: A Longitudinal Neuropsychological Study
- Open Access
- 6 August 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
Impact of Age on the Diagnostic Yield of Routine EEG in People With Childhood or Juvenile Absence Epilepsy: A Cross‐Sectional Study
Background: We aimed to identify the proportion of individuals with a confirmed diagnosis of childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE) who show a negative routine EEG (rEEG), and to determine the main factors associated with this finding. Methods: Individuals with CAE or JAE underwent both an rEEG and a 24‐h ambulatory EEG (24‐h‐aEEG). Participants were classified as ‘rEEG positive’ if generalised spike–wave discharges (GSWs) and/or typical absences (TAs) were observed, and as ‘rEEG negative’ if no such features were detected. 24‐h‐aEEG recordings served as the ground truth to confirm the diagnosis in cases with a negative rEEG. Results: Eighty‐two individuals [40/82 (48.8%) females; mean age 12.5 ± 5.6 years] were included, of whom 39/82 (47.6%) were not receiving anti‐seizure medications (ASMs) at the time of the EEG. Overall, 31/82 (37.8%) had a negative rEEG, including 10/39 (25.6%) in the cohort of ASM‐naïve individuals. Compared with rEEG‐positive participants, those in the rEEG‐negative group had a later age at epilepsy onset (12.1 ± 4.5 years; p < 0.001) and were older at the time of EEG (16.5 ± 5.3 years; p < 0.0001). Older age at EEG emerged as significantly associated with a negative rEEG (OR = 1.23; 95% CI = 1.03–1.46; p = 0.019), independent of age at onset, epilepsy syndrome (CAE or JAE) and ASM exposure. Sensitivity analyses confirmed the association between older age and rEEG negativity across all cohorts: ASM‐naïve individuals (OR = 1.41; 95% CI = 1.12–1.78), CAE (OR = 1.27; 95% CI = 1.02–1.58), and JAE (OR = 1.36; 95% CI 1.09–1.69) groups. Youden's exploratory analysis identified ≥ 14 years as the optimal threshold for predicting a rEEG negative. Conclusion: Age significantly reduces the diagnostic yield of rEEG in CAE and JAE, regardless of ASM treatment.
- 6 August 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
Open AccessImpact of Age on the Diagnostic Yield of Routine EEG in People With Childhood or Juvenile Absence Epilepsy: A Cross‐Sectional Study
Background: We aimed to identify the proportion of individuals with a confirmed diagnosis of childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE) who show a negative routine EEG (rEEG), and to determine the main factors associated with this finding. Methods: Individuals with CAE or JAE underwent both an rEEG and a 24‐h ambulatory EEG (24‐h‐aEEG). Participants were classified as ‘rEEG positive’ if generalised spike–wave discharges (GSWs) and/or typical absences (TAs) were observed, and as ‘rEEG negative’ if no such features were detected. 24‐h‐aEEG recordings served as the ground truth to confirm the diagnosis in cases with a negative rEEG. Results: Eighty‐two individuals [40/82 (48.8%) females; mean age 12.5 ± 5.6 years] were included, of whom 39/82 (47.6%) were not receiving anti‐seizure medications (ASMs) at the time of the EEG. Overall, 31/82 (37.8%) had a negative rEEG, including 10/39 (25.6%) in the cohort of ASM‐naïve individuals. Compared with rEEG‐positive participants, those in the rEEG‐negative group had a later age at epilepsy onset (12.1 ± 4.5 years; p < 0.001) and were older at the time of EEG (16.5 ± 5.3 years; p < 0.0001). Older age at EEG emerged as significantly associated with a negative rEEG (OR = 1.23; 95% CI = 1.03–1.46; p = 0.019), independent of age at onset, epilepsy syndrome (CAE or JAE) and ASM exposure. Sensitivity analyses confirmed the association between older age and rEEG negativity across all cohorts: ASM‐naïve individuals (OR = 1.41; 95% CI = 1.12–1.78), CAE (OR = 1.27; 95% CI = 1.02–1.58), and JAE (OR = 1.36; 95% CI 1.09–1.69) groups. Youden's exploratory analysis identified ≥ 14 years as the optimal threshold for predicting a rEEG negative. Conclusion: Age significantly reduces the diagnostic yield of rEEG in CAE and JAE, regardless of ASM treatment.
- Open Access
- 2 August 2026
- Published by Elsevier in SSRN Electronic Journal
EXPANDING THE GENETIC LANDSCAPE OF DRAVET SPECTRUM: A RARE HDAC4 MISSENSE VARIANT IDENTIFIED THROUGH EXOME SEQUENCING
Dravet spectrum, a phenotype previously referred to as Severe Myoclonic Epilepsy Borderland (SMEB), is genetically heterogeneous and most frequently associated with pathogenic variants in SCN1A. However, additional molecular pathways are increasingly implicated. Here, we report a Dravet spectrum patient identified through whole-exome sequencing carrying a rare heterozygous missense variant in HDAC4 (p.Arg543Trp). The variant was inherited from an unaffected father, indicating incomplete penetrance. The affected residue lies within the central regulatory domain of HDAC4 and is evolutionarily conserved. Structural modelling revealed subtle disturbance of local polar interactions without major backbone rearrangement, consistent with a mild regulatory perturbation aligned with the attenuated Dravet spectrum phenotype. No additional clinically relevant variants were identified. These findings expand the genetic and phenotypic landscape of Dravet spectrum, illustrating how altered transcriptional regulation may contribute to disease.
- 2 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEXPANDING THE GENETIC LANDSCAPE OF DRAVET SPECTRUM: A RARE HDAC4 MISSENSE VARIANT IDENTIFIED THROUGH EXOME SEQUENCING
Dravet spectrum, a phenotype previously referred to as Severe Myoclonic Epilepsy Borderland (SMEB), is genetically heterogeneous and most frequently associated with pathogenic variants in SCN1A. However, additional molecular pathways are increasingly implicated. Here, we report a Dravet spectrum patient identified through whole-exome sequencing carrying a rare heterozygous missense variant in HDAC4 (p.Arg543Trp). The variant was inherited from an unaffected father, indicating incomplete penetrance. The affected residue lies within the central regulatory domain of HDAC4 and is evolutionarily conserved. Structural modelling revealed subtle disturbance of local polar interactions without major backbone rearrangement, consistent with a mild regulatory perturbation aligned with the attenuated Dravet spectrum phenotype. No additional clinically relevant variants were identified. These findings expand the genetic and phenotypic landscape of Dravet spectrum, illustrating how altered transcriptional regulation may contribute to disease.
- 14 May 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
The bidirectional association of epilepsy with Alzheimer's disease and other neurodegenerative dementias: A longitudinal observational study on the UK Biobank
Background: Converging evidence supports a bidirectional link between epilepsy and Alzheimer's disease (AD). Limited data are available regarding the association of epilepsy with frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB). Objective: To estimate the bidirectional association between epilepsy and AD, FTD, and DLB in the UK Biobank, a large, multi-source healthcare dataset. Methods: Epilepsy, AD, FTD, and DLB cohorts were extracted. Cox proportional-hazard models were used to compare the AD risk in the epilepsy cohort against matched controls, and the epilepsy risk in the AD cohort against matched controls. Prevalent association of epilepsy with FTD and DLB was assessed using Chi-squared/Fisher test. Results: Hazard-ratio (HR) for AD in the epilepsy population versus controls was 2.5 (1.8–3.4, p < 0.001); HR increased when epilepsy was diagnosed in the sixth-seventh decade and in individuals with epilepsy carrying the APOE ε4 allele. Conversely, HR for epilepsy in AD versus controls was 14.8 (9.7–22.5, p < 0.001). Epilepsy prevalence was higher in the FTD population compared to controls, with prevalence ratio (PR) of 5.3 (2.4–11.8, p = 0.001). Epilepsy PR in DLB versus controls approached but did not achieve statistical significance (2.4, 1.0–5.7, p = 0.068). Conclusions: Our findings reinforce the notion of a bidirectional association between epilepsy and AD, providing proof-of-concept that epilepsy, especially late-onset, may be successfully integrated into AD risk frameworks. Furthermore, we found a high prevalence of epilepsy in the FTD population. Careful stratification of individuals with epilepsy could offer an opportunity to identify those at higher risk of future or covert AD and neurodegeneration.
- 14 May 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
The bidirectional association of epilepsy with Alzheimer's disease and other neurodegenerative dementias: A longitudinal observational study on the UK Biobank
Background: Converging evidence supports a bidirectional link between epilepsy and Alzheimer's disease (AD). Limited data are available regarding the association of epilepsy with frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB). Objective: To estimate the bidirectional association between epilepsy and AD, FTD, and DLB in the UK Biobank, a large, multi-source healthcare dataset. Methods: Epilepsy, AD, FTD, and DLB cohorts were extracted. Cox proportional-hazard models were used to compare the AD risk in the epilepsy cohort against matched controls, and the epilepsy risk in the AD cohort against matched controls. Prevalent association of epilepsy with FTD and DLB was assessed using Chi-squared/Fisher test. Results: Hazard-ratio (HR) for AD in the epilepsy population versus controls was 2.5 (1.8–3.4, p < 0.001); HR increased when epilepsy was diagnosed in the sixth-seventh decade and in individuals with epilepsy carrying the APOE ε4 allele. Conversely, HR for epilepsy in AD versus controls was 14.8 (9.7–22.5, p < 0.001). Epilepsy prevalence was higher in the FTD population compared to controls, with prevalence ratio (PR) of 5.3 (2.4–11.8, p = 0.001). Epilepsy PR in DLB versus controls approached but did not achieve statistical significance (2.4, 1.0–5.7, p = 0.068). Conclusions: Our findings reinforce the notion of a bidirectional association between epilepsy and AD, providing proof-of-concept that epilepsy, especially late-onset, may be successfully integrated into AD risk frameworks. Furthermore, we found a high prevalence of epilepsy in the FTD population. Careful stratification of individuals with epilepsy could offer an opportunity to identify those at higher risk of future or covert AD and neurodegeneration.
- Open Access
- 6 February 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (2) , 701-716
Long-Term Impact of Cenobamate on Cognition, Adaptive Behavior, and Quality of Life in Patients with Tuberous Sclerosis Complex
Introduction Cenobamate is a recent therapeutic option for epilepsy, but few studies have investigated its impact on cognitive and emotional/behavioral functioning. The aim of our study was to assess cognitive function, adaptive behavior, quality of life, and parental stress in late adolescents and young adults with tuberous sclerosis complex (TSC) and drug-resistant epilepsy, treated with add-on cenobamate over a 12-month period using standardized neuropsychological tests. Methods Our prospective observational study included 22 patients, aged 18 to 24 years with a diagnosis of TSC and drug-resistant epilepsy who started cenobamate add-on therapy for improving seizure control. At baseline and after 3- and 12-month follow-ups, participants completed a neuropsychological standardized assessment of executive functions (Epitrack©), adaptive behavior (VABS-II), quality of life (QOL), and parental stress (PSI). Cognitive functions (WAIS-IV) were reassessed only at the 12-month follow-up. Changes in standardized scores over time were analyzed using Friedman’s two-way analysis of variance and post hoc analysis. Relationships between demographic/clinical variables and neuropsychological scores were analyzed using correlation analysis. Results Our study highlighted a statistically significant improvement in Epitrack, PSI-4-SF, and QOL scores after 3- or 12-month follow-ups (p < 0.05). Stability was maintained for the WAIS and VABS-II scores. The subjects with TSC2 mutations showed significantly lower IQ scores than those carrying TSC1 mutations (p < 0.001). Total parental stress (PSI) was significantly related to the total score of VABS-II at both baseline (p = 0.003) and 12 months (p = 0.001). Conclusion Our study suggested that cenobamate add-on therapy was effective and generally well tolerated in this cohort. Neuropsychological assessments suggest beneficial effects on executive functions, emotional well-being, social functioning, and quality of life. Furthermore, an improvement in parental stress also emerged. These findings could support clinicians in the decision-making process, evaluating cenobamate as an early treatment option in drug-resistant epilepsy.
- 6 February 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (2) , 701-716
Open AccessLong-Term Impact of Cenobamate on Cognition, Adaptive Behavior, and Quality of Life in Patients with Tuberous Sclerosis Complex
Introduction Cenobamate is a recent therapeutic option for epilepsy, but few studies have investigated its impact on cognitive and emotional/behavioral functioning. The aim of our study was to assess cognitive function, adaptive behavior, quality of life, and parental stress in late adolescents and young adults with tuberous sclerosis complex (TSC) and drug-resistant epilepsy, treated with add-on cenobamate over a 12-month period using standardized neuropsychological tests. Methods Our prospective observational study included 22 patients, aged 18 to 24 years with a diagnosis of TSC and drug-resistant epilepsy who started cenobamate add-on therapy for improving seizure control. At baseline and after 3- and 12-month follow-ups, participants completed a neuropsychological standardized assessment of executive functions (Epitrack©), adaptive behavior (VABS-II), quality of life (QOL), and parental stress (PSI). Cognitive functions (WAIS-IV) were reassessed only at the 12-month follow-up. Changes in standardized scores over time were analyzed using Friedman’s two-way analysis of variance and post hoc analysis. Relationships between demographic/clinical variables and neuropsychological scores were analyzed using correlation analysis. Results Our study highlighted a statistically significant improvement in Epitrack, PSI-4-SF, and QOL scores after 3- or 12-month follow-ups (p < 0.05). Stability was maintained for the WAIS and VABS-II scores. The subjects with TSC2 mutations showed significantly lower IQ scores than those carrying TSC1 mutations (p < 0.001). Total parental stress (PSI) was significantly related to the total score of VABS-II at both baseline (p = 0.003) and 12 months (p = 0.001). Conclusion Our study suggested that cenobamate add-on therapy was effective and generally well tolerated in this cohort. Neuropsychological assessments suggest beneficial effects on executive functions, emotional well-being, social functioning, and quality of life. Furthermore, an improvement in parental stress also emerged. These findings could support clinicians in the decision-making process, evaluating cenobamate as an early treatment option in drug-resistant epilepsy.
- Open Access
- 10 January 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 92
Do Cenobamate Pharmacokinetics Change with Co-Administered Antiseizure Medications? An Exploratory Analysis of Responder Patients with Focal Drug-Resistant Epilepsy
Background: Cenobamate (CNB) is an anti-seizure medication (ASM) approved for the treatment of drug-resistant focal epilepsy in adults. Notwithstanding significant proof of efficacy, real-world pharmacokinetics (PK) data are lacking, particularly regarding sex-based variations and the effect of concomitant ASMs. This exploratory study aimed to investigate the PK profile of CNB in responder adults with drug-resistant focal epilepsy and assess potential relationship with concomitant ASMs and clinical variables. Methods: We enrolled 17 patients receiving add-on CNB. The concentration-to-dose ratio (C/D), incremental slope (ΔC/ΔD), and dose-to-concentration AUC were calculated. Enrolled individuals were stratified into three exposure clusters (low, medium, and high). Univariate ANOVA was used to explore associations between PK parameters, clinical variables and concomitant ASMs. Results: Sex appeared to be associated with AUC cluster classification (p = 0.026), showing females predominating in the high-exposure group. A nonlinear dose-concentration relationship emerged from the ΔC/ΔD analysis, showing steeper slopes at low doses (12.5–50 mg), great variability at higher doses (100–200 mg), and a negative slope in some individuals. Higher CNB concentrations were observed in patients co-treated with lacosamide, while concomitant topiramate was associated with lower exposure. Carbamazepine and valproate showed non-significant trends consistent with their known enzyme-inducing and inhibiting properties. Conclusions: PK of CNB appears highly variable and seems to be influenced by sex and concomitant ASMs. These findings highlight the importance of therapeutic drug monitoring and individualized titration strategies to optimize efficacy and safety in clinical practice. These results should be regarded as exploratory and hypothesis-generating due to the small and monocentric sample size and need to be confirmed in larger, multicenter cohorts.
- 10 January 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 92
Open AccessDo Cenobamate Pharmacokinetics Change with Co-Administered Antiseizure Medications? An Exploratory Analysis of Responder Patients with Focal Drug-Resistant Epilepsy
Background: Cenobamate (CNB) is an anti-seizure medication (ASM) approved for the treatment of drug-resistant focal epilepsy in adults. Notwithstanding significant proof of efficacy, real-world pharmacokinetics (PK) data are lacking, particularly regarding sex-based variations and the effect of concomitant ASMs. This exploratory study aimed to investigate the PK profile of CNB in responder adults with drug-resistant focal epilepsy and assess potential relationship with concomitant ASMs and clinical variables. Methods: We enrolled 17 patients receiving add-on CNB. The concentration-to-dose ratio (C/D), incremental slope (ΔC/ΔD), and dose-to-concentration AUC were calculated. Enrolled individuals were stratified into three exposure clusters (low, medium, and high). Univariate ANOVA was used to explore associations between PK parameters, clinical variables and concomitant ASMs. Results: Sex appeared to be associated with AUC cluster classification (p = 0.026), showing females predominating in the high-exposure group. A nonlinear dose-concentration relationship emerged from the ΔC/ΔD analysis, showing steeper slopes at low doses (12.5–50 mg), great variability at higher doses (100–200 mg), and a negative slope in some individuals. Higher CNB concentrations were observed in patients co-treated with lacosamide, while concomitant topiramate was associated with lower exposure. Carbamazepine and valproate showed non-significant trends consistent with their known enzyme-inducing and inhibiting properties. Conclusions: PK of CNB appears highly variable and seems to be influenced by sex and concomitant ASMs. These findings highlight the importance of therapeutic drug monitoring and individualized titration strategies to optimize efficacy and safety in clinical practice. These results should be regarded as exploratory and hypothesis-generating due to the small and monocentric sample size and need to be confirmed in larger, multicenter cohorts.
- Open Access
Climate change and hyponatremia‐related hospital admissions in people with focal epilepsy exposed to carbamazepine or its derivatives
Objective: To estimate the proportion of individuals with focal epilepsy treated with at least one among carbamazepine (CBZ), oxcarbazepine (OXC), or eslicarbazepine (ESL), who were hospitalized due to hyponatremia‐related symptoms in 2024, and to test the hypothesis that there is an association with climatic variables. Methods: We undertook a prospective study in which people with focal epilepsy treated with at least one of the target drugs and at least one attendance in 2024 formed the study cohort. Individuals who were admitted or seen as outpatients for hyponatremia in 2024 were considered cases and the rest considered controls. Climate analysis was performed in Lamezia Terme, Calabria, Italy. Results: Seventeen of the entire cohort of 105 (16.2%) had hyponatremia‐related hospitalizations. Older age (odds ratio [OR] = 1.07, 95% confidence interval [CI] = 1.03–1.12; p = .001) and exposure to OXC/ESL compared to CBZ (OR = 4.15, 95% CI = 1.20–14.32; p = .02) emerged as significant predictors of the events. Thirteen of the 17 cases (76.5%) currently reside on the Calabria coastline. Twelve of 17 events (70.6%) occurred between June and August. Among climatic variables, heatwaves (OR = 4.87, 95% CI = 1.75–13.50; p = .002) and tropical nights (night‐temperature ≥20°C) (OR = 2.72, 95% CI = 1.02–7.27; p = .046) were the most significant predictors of the events. Forecasting models based on 10 consecutive days of recordings prior to the events revealed trends of rising temperatures preceding the events. Significance: We report a high rate of hyponatremia‐related hospitalizations among people with epilepsy occurring predominantly during summer. Climate change–related events, such as heatwaves and tropical nights, may trigger hyponatremia symptoms. Climate–regional vulnerability should therefore also be considered when selecting antiseizure medications and when counseling patients. We encourage interdisciplinary collaboration between clinicians and climate scientists in this emerging critical area.
Open AccessClimate change and hyponatremia‐related hospital admissions in people with focal epilepsy exposed to carbamazepine or its derivatives
Objective: To estimate the proportion of individuals with focal epilepsy treated with at least one among carbamazepine (CBZ), oxcarbazepine (OXC), or eslicarbazepine (ESL), who were hospitalized due to hyponatremia‐related symptoms in 2024, and to test the hypothesis that there is an association with climatic variables. Methods: We undertook a prospective study in which people with focal epilepsy treated with at least one of the target drugs and at least one attendance in 2024 formed the study cohort. Individuals who were admitted or seen as outpatients for hyponatremia in 2024 were considered cases and the rest considered controls. Climate analysis was performed in Lamezia Terme, Calabria, Italy. Results: Seventeen of the entire cohort of 105 (16.2%) had hyponatremia‐related hospitalizations. Older age (odds ratio [OR] = 1.07, 95% confidence interval [CI] = 1.03–1.12; p = .001) and exposure to OXC/ESL compared to CBZ (OR = 4.15, 95% CI = 1.20–14.32; p = .02) emerged as significant predictors of the events. Thirteen of the 17 cases (76.5%) currently reside on the Calabria coastline. Twelve of 17 events (70.6%) occurred between June and August. Among climatic variables, heatwaves (OR = 4.87, 95% CI = 1.75–13.50; p = .002) and tropical nights (night‐temperature ≥20°C) (OR = 2.72, 95% CI = 1.02–7.27; p = .046) were the most significant predictors of the events. Forecasting models based on 10 consecutive days of recordings prior to the events revealed trends of rising temperatures preceding the events. Significance: We report a high rate of hyponatremia‐related hospitalizations among people with epilepsy occurring predominantly during summer. Climate change–related events, such as heatwaves and tropical nights, may trigger hyponatremia symptoms. Climate–regional vulnerability should therefore also be considered when selecting antiseizure medications and when counseling patients. We encourage interdisciplinary collaboration between clinicians and climate scientists in this emerging critical area.
- Open Access
- 31 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (1) , 295
Novel KCNQ2 Variants Related to a Variable Phenotypic Spectrum Ranging from Epilepsy with Auditory Features to Severe Developmental and Epileptic Encephalopathies
Pathogenic KCNQ2 variants are associated with neonatal epilepsies, ranging from self-limited neonatal epilepsy to KCNQ2–developmental and epileptic encephalopathy (DEE). In this study, next-generation sequencing was performed, applying a panel of 142 epilepsy genes on three unrelated individuals and affected family members, showing a wide variability in the epileptic spectrum. The genetic analysis revealed two likely pathogenic missense variants (c.1378G>A and c.2251T>G) and the already-reported pathogenic splice site (c.1631+1G>A) in KCNQ2 (HGNC:6296). The phenotypes observed in the affected members of family 1, which shared the c.2251T>G variant, were epilepsy with auditory features (EAFs), focal epilepsy, and generalized epilepsy, and none of them suffered from neonatal seizures. The gene panel contained further genes related to EAFs (LGI1, RELN, SCN1A, and DEPDC5), which were tested with negative results. The phenotypes observed in family 2 members, sharing the splice site variant, were neonatal seizures and focal epilepsy in childhood. The last unrelated proband, harboring the de novo missense c.1378G>A, presented a clinical phenotype consistent with DEE. In conclusion, we identified two unreported KCNQ2 variants, and report a proband with EAFs and individuals without typical KCNQ2 neonatal seizures. Our study underscores the extreme variability in the phenotypic spectrum of KCNQ2-related epilepsies and unveils the prospect of its inclusion in screening panels for EAFs.
- 31 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (1) , 295
Open AccessNovel KCNQ2 Variants Related to a Variable Phenotypic Spectrum Ranging from Epilepsy with Auditory Features to Severe Developmental and Epileptic Encephalopathies
Pathogenic KCNQ2 variants are associated with neonatal epilepsies, ranging from self-limited neonatal epilepsy to KCNQ2–developmental and epileptic encephalopathy (DEE). In this study, next-generation sequencing was performed, applying a panel of 142 epilepsy genes on three unrelated individuals and affected family members, showing a wide variability in the epileptic spectrum. The genetic analysis revealed two likely pathogenic missense variants (c.1378G>A and c.2251T>G) and the already-reported pathogenic splice site (c.1631+1G>A) in KCNQ2 (HGNC:6296). The phenotypes observed in the affected members of family 1, which shared the c.2251T>G variant, were epilepsy with auditory features (EAFs), focal epilepsy, and generalized epilepsy, and none of them suffered from neonatal seizures. The gene panel contained further genes related to EAFs (LGI1, RELN, SCN1A, and DEPDC5), which were tested with negative results. The phenotypes observed in family 2 members, sharing the splice site variant, were neonatal seizures and focal epilepsy in childhood. The last unrelated proband, harboring the de novo missense c.1378G>A, presented a clinical phenotype consistent with DEE. In conclusion, we identified two unreported KCNQ2 variants, and report a proband with EAFs and individuals without typical KCNQ2 neonatal seizures. Our study underscores the extreme variability in the phenotypic spectrum of KCNQ2-related epilepsies and unveils the prospect of its inclusion in screening panels for EAFs.